Astera Labs Stock Jumps in May on Q1 Beat and Scorpio Switch Launch

What happened

Astera Labs reported a stellar Q1 with revenue up 93% YoY and introduced its Scorpio X-Series fabric switch, which management expects to be the largest product this year. However, the Q2 guidance revealed a significant step-down in GAAP gross margin to ~73% from 76.3% in Q1, partly due to a non-cash customer agreement impact. The company's customer concentration remains extreme, with the top five direct customers accounting for 90% of Q1 revenue and a single end customer exceeding 70% of total revenue in 2025. CEO Jitendra Mohan and other insiders sold substantial shares in March-April 2026, raising governance concerns. The market's bullish reaction in May overlooked these risks, pushing the stock to a P/E of 167x, which embeds continued hypergrowth and margin recovery.

Implication

The current valuation at ~$215 offers no margin of safety, pricing in a perfect execution scenario that the Q2 margin guide already contradicts. Near-term checkpoints include Q2 actuals (revenue $355-365M, gross margin ~73%) and Scorpio X-Series production ramp in 2H'26. If gross margin stays near 73% for another quarter, the thesis weakens as customer economics appear structurally impaired. Conversely, if Scorpio ramps on schedule and gross margin rebounds to 75%+, the stock could re-rate higher. Until then, the risk/reward is unattractive; a better entry is near $180, the report's attractive entry level.

Thesis delta

The strong Q1 and new switch product confirm robust demand, but the Q2 margin guidance and insider selling temper the bullish narrative. The thesis shifts from 'pure growth story' to a 'wait for proof of margin stability' trade. No change to WAIT rating; the near-term catalysts are now more binary.